These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 32678144)

  • 21. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria.
    Malkin EM; Diemert DJ; McArthur JH; Perreault JR; Miles AP; Giersing BK; Mullen GE; Orcutt A; Muratova O; Awkal M; Zhou H; Wang J; Stowers A; Long CA; Mahanty S; Miller LH; Saul A; Durbin AP
    Infect Immun; 2005 Jun; 73(6):3677-85. PubMed ID: 15908397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of adjuvants for clinical trials performed with Plasmodium falciparum AMA1 in rabbits.
    Younis S; Faber BW; Kocken CHM; Remarque EJ
    BMC Immunol; 2019 Jul; 20(1):25. PubMed ID: 31362695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibodies to polymorphic invasion-inhibitory and non-Inhibitory epitopes of Plasmodium falciparum apical membrane antigen 1 in human malaria.
    Mugyenyi CK; Elliott SR; McCallum FJ; Anders RF; Marsh K; Beeson JG
    PLoS One; 2013; 8(7):e68304. PubMed ID: 23861883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.
    Sirima SB; Durier C; Kara L; Houard S; Gansane A; Loulergue P; Bahuaud M; Benhamouda N; Nebié I; Faber B; Remarque E; Launay O;
    Vaccine; 2017 Oct; 35(45):6218-6227. PubMed ID: 28947345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.
    Sheehy SH; Duncan CJ; Elias SC; Biswas S; Collins KA; O'Hara GA; Halstead FD; Ewer KJ; Mahungu T; Spencer AJ; Miura K; Poulton ID; Dicks MD; Edwards NJ; Berrie E; Moyle S; Colloca S; Cortese R; Gantlett K; Long CA; Lawrie AM; Gilbert SC; Doherty T; Nicosia A; Hill AV; Draper SJ
    PLoS One; 2012; 7(2):e31208. PubMed ID: 22363582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-based design of a strain transcending AMA1-RON2L malaria vaccine.
    Patel PN; Dickey TH; Diouf A; Salinas ND; McAleese H; Ouahes T; Long CA; Miura K; Lambert LE; Tolia NH
    Nat Commun; 2023 Sep; 14(1):5345. PubMed ID: 37660103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Limited antigenic diversity of Plasmodium falciparum apical membrane antigen 1 supports the development of effective multi-allele vaccines.
    Terheggen U; Drew DR; Hodder AN; Cross NJ; Mugyenyi CK; Barry AE; Anders RF; Dutta S; Osier FH; Elliott SR; Senn N; Stanisic DI; Marsh K; Siba PM; Mueller I; Richards JS; Beeson JG
    BMC Med; 2014 Oct; 12():183. PubMed ID: 25319190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-apical membrane antigen 1 (AMA1) IgGs from Malian children interfere with functional activity of AMA1 IgGs as judged by growth inhibition assay.
    Miura K; Perera S; Brockley S; Zhou H; Aebig JA; Moretz SE; Miller LH; Doumbo OK; Sagara I; Dicko A; Ellis RD; Long CA
    PLoS One; 2011; 6(6):e20947. PubMed ID: 21695140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Process development and preclinical evaluation of a major
    Somanathan A; Mian SY; Chaddha K; Uchoi S; Bharti PK; Tandon R; Gaur D; Chauhan VS
    Front Immunol; 2022; 13():1005332. PubMed ID: 36211427
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparison of biological activity of human anti-apical membrane antigen-1 antibodies induced by natural infection and vaccination.
    Miura K; Zhou H; Moretz SE; Diouf A; Thera MA; Dolo A; Doumbo O; Malkin E; Diemert D; Miller LH; Mullen GE; Long CA
    J Immunol; 2008 Dec; 181(12):8776-83. PubMed ID: 19050299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A malaria vaccine protects
    Srinivasan P; Baldeviano GC; Miura K; Diouf A; Ventocilla JA; Leiva KP; Lugo-Roman L; Lucas C; Orr-Gonzalez S; Zhu D; Villasante E; Soisson L; Narum DL; Pierce SK; Long CA; Diggs C; Duffy PE; Lescano AG; Miller LH
    NPJ Vaccines; 2017; 2():. PubMed ID: 28804644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model.
    Dutta S; Sullivan JS; Grady KK; Haynes JD; Komisar J; Batchelor AH; Soisson L; Diggs CL; Heppner DG; Lanar DE; Collins WE; Barnwell JW
    PLoS One; 2009 Dec; 4(12):e8138. PubMed ID: 19997632
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria.
    Stowers AW; Kennedy MC; Keegan BP; Saul A; Long CA; Miller LH
    Infect Immun; 2002 Dec; 70(12):6961-7. PubMed ID: 12438375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response.
    Kennedy MC; Wang J; Zhang Y; Miles AP; Chitsaz F; Saul A; Long CA; Miller LH; Stowers AW
    Infect Immun; 2002 Dec; 70(12):6948-60. PubMed ID: 12438374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neutralising antibodies block the function of Rh5/Ripr/CyRPA complex during invasion of Plasmodium falciparum into human erythrocytes.
    Healer J; Wong W; Thompson JK; He W; Birkinshaw RW; Miura K; Long CA; Soroka V; Søgaard TMM; Jørgensen T; de Jongh WA; Weir C; Svahn E; Czabotar PE; Tham WH; Mueller I; Barlow PN; Cowman AF
    Cell Microbiol; 2019 Jul; 21(7):e13030. PubMed ID: 30965383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Specificity of the protective antibody response to apical membrane antigen 1.
    Hodder AN; Crewther PE; Anders RF
    Infect Immun; 2001 May; 69(5):3286-94. PubMed ID: 11292751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibodies to malaria peptide mimics inhibit Plasmodium falciparum invasion of erythrocytes.
    Casey JL; Coley AM; Anders RF; Murphy VJ; Humberstone KS; Thomas AW; Foley M
    Infect Immun; 2004 Feb; 72(2):1126-34. PubMed ID: 14742560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of Plasmodium falciparum reticulocyte binding protein homologue 5-interacting protein, PfRipr, as a highly conserved blood-stage malaria vaccine candidate.
    Ntege EH; Arisue N; Ito D; Hasegawa T; Palacpac NMQ; Egwang TG; Horii T; Takashima E; Tsuboi T
    Vaccine; 2016 Nov; 34(46):5612-5622. PubMed ID: 27692771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generation of Plasmodium falciparum parasite-inhibitory antibodies by immunization with recombinantly-expressed CyRPA.
    Favuzza P; Blaser S; Dreyer AM; Riccio G; Tamborrini M; Thoma R; Matile H; Pluschke G
    Malar J; 2016 Mar; 15():161. PubMed ID: 26979066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Plasmodium vivax Plasmid DNA- and Adenovirus-Vectored Malaria Vaccine Encoding Blood-Stage Antigens AMA1 and MSP1
    Obaldia N; Stockelman MG; Otero W; Cockrill JA; Ganeshan H; Abot EN; Zhang J; Limbach K; Charoenvit Y; Doolan DL; Tang DC; Richie TL
    Clin Vaccine Immunol; 2017 Apr; 24(4):. PubMed ID: 28179404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.